It has been recently described that, in premenopausal women with hormone receptor-positive (HR+) breast cancer, ovarian function suppression using GnRH analogs such as goserelin and leuprolide has become an important therapeutic strategy [82]. Here, GNRH1 is linked to breast carcinoma.